MedTrace Logo

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-08-26

Study results available
· View outcomes & findings →

Summary

An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

AbobotulinumtoxinA

AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2019-11-07
Completion
2019-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687736 on ClinicalTrials.gov